Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

NCT06677190 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Ovarian Carcinoma
Endometrial Cancer
Uterine Cancer
Cervical Cancer
Vulvar Cancer
Gynecologic Cancer
Vaginal Cancer

Interventions

DRUG: Belzutifan

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]